SANKYO CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,633 JPY | -1.98% |
|
-1.21% | -0.71% |
| Apr. 08 | AstraZeneca hails neurological data for Ultomiris, Soliris | AN |
| Apr. 08 | AstraZeneca's, Daiichi's Enhertu receives US FDA approval | AN |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Casinos & Gaming
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -0.71% | 2.36B | D+ | ||
| +13.93% | 8.46B | C | ||
| -23.96% | 718M | B- | ||
| +10.12% | 695M | C- | ||
| +31.17% | 367M | - | - | |
| +3.44% | 342M | C- | ||
| +4.63% | 340M | - | - | |
| +16.30% | 188M | - | - | |
| +27.77% | 101M | - | - | |
| -28.70% | 62.86M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 6417 Stock
- Ratings Sankyo Co., Ltd.
